On June 17, 2025, Citigroup analyst Geoff Meacham initiated coverage on Protagonist Therapeutics (PTGX, Financial), assigning a 'Buy' rating to the stock. This rating indicates a positive outlook for PTGX by Citigroup, suggesting that investors should consider purchasing the stock at its current levels.
Accompanying the 'Buy' rating, a price target (PT) of $72.00 USD has been set for Protagonist Therapeutics (PTGX, Financial). This price target reflects the potential upside in the company's stock price, according to Citigroup's projections.
The initiation of coverage by Citigroup marks a new endorsement for Protagonist Therapeutics (PTGX, Financial), as there was no prior rating or price target from Citigroup before this announcement. Investors may view this coverage as a vote of confidence in the company's future prospects.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 9 analysts, the average target price for Protagonist Therapeutics Inc (PTGX, Financial) is $69.00 with a high estimate of $82.00 and a low estimate of $41.00. The average target implies an upside of 26.23% from the current price of $54.66. More detailed estimate data can be found on the Protagonist Therapeutics Inc (PTGX) Forecast page.
Based on the consensus recommendation from 10 brokerage firms, Protagonist Therapeutics Inc's (PTGX, Financial) average brokerage recommendation is currently 1.8, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
